Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 18 (3) 890-900
Year:
2012
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
1
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, K07 CA148894, U10 CA032291, CA35415, CA33601, P50 CA127003-05, U10 CA071323, R01 CA118553, R01 CA149222-03, U10 CA077658, R01 CA149222, U10 CA045564, U10 CA035279, U10 CA045808, U10 CA031946, CA77651, R01 CA151993, U10 CA033601, U10 CA045389, R01CA118553, U10 CA077597, UL1 RR025741, U10 CA035421, U10 CA114558, U10 CA045418, U10 CA077440, R01 CA118553-05, CA46282, R01 CA151993-03, CA32101, U10 CA041287, K07 CA148894-02, U10 CA047559, U10 CA077651, CA38926, U10 CA033601-30S1, CA47559, U10 CA031946-31, U10 CA074811, U10 CA047642, P50 CA127003, CA23318, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
                                 
Networks:
 
Study
CALGB-150705
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-89803
Phases:
N/A, 3
Keywords:
colorectal cancer, RAS, biomarker, prognosis, response, resistance